Compare BCPC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCPC | GPCR |
|---|---|---|
| Founded | 1967 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | N/A | 2023 |
| Metric | BCPC | GPCR |
|---|---|---|
| Price | $173.25 | $73.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $176.00 | $103.09 |
| AVG Volume (30 Days) | 156.7K | ★ 1.2M |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 22.48 | N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $1,013,548,000.00 | N/A |
| Revenue This Year | $10.41 | N/A |
| Revenue Next Year | $6.36 | N/A |
| P/E Ratio | $38.10 | ★ N/A |
| Revenue Growth | ★ 7.55 | N/A |
| 52 Week Low | $139.17 | $13.22 |
| 52 Week High | $177.40 | $94.90 |
| Indicator | BCPC | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.11 | 42.55 |
| Support Level | $167.80 | $86.10 |
| Resistance Level | $176.35 | $92.06 |
| Average True Range (ATR) | 3.41 | 5.00 |
| MACD | 0.46 | -2.43 |
| Stochastic Oscillator | 75.78 | 6.97 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.